Odyssey Therapeutics reports Q2 2026 results, plans next OD-001 trials in second half of 2026
The company said Phase 2a monotherapy data on OD-001 will be presented in October, with a combination trial and a Phase 2b trial slated to start later in 2026, backed by $433.1 million in cash.
SEC filing